Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | TVI-AST-008: adoptive neoantigen-specific T-cell immunotherapy in MGMT-u glioblastoma

Tolga Tuncer, MD, University of Kansas Medical Center, Kansas City, KS, presents initial analysis of TVI-AST-008 (NCT05685004), evaluating adoptive neoantigen-specific T-cell immunotherapy for MGMT-unmethylated (MGMT-u) glioblastoma. Tumor cells are primed in vivo and expanded ex vivo, allowing patients to avoid immune-suppressing chemoradiotherapy. Results show a good safety profile with no ICANS or neurotoxicity reported, and the therapy has received FDA Orphan Product designation, which provides support for further studies. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.